Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Camillo Porta
Observed names:
C. Porta,
Porta, Camillo
Institutions:
Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari,
University of Bari Aldo Moro
Observed institutions:
Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari,
Health Economics and Outcomes Research (United Kingdom),
Policlinico San Matteo Fondazione,
University of Bari Aldo Moro
ORCID:
0000-0003-2412-1563
Observed ORCID:
0000-0003-2412-1563
OpenAlex ID:
A5039774160
Outcomes of Patients with Metastatic Non–clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
2026
·
Kosuke Takemura
, Jeffrey Graham
, et al.
·
European Urology Oncology
·
6
PDF
Identification of Predictive Genomic Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma: A Comprehensive Analysis of Real-World Clinicogenomic Data
2026
·
Mimma Rizzo
, Gaetano Pezzicoli
, et al.
·
JCO Precision Oncology
·
2
PDF
Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and bone metastasis: Updated subgroup analysis of the phase 3 CheckMate-9ER trial.
2026
·
Andrea B. Apolo
, Bernard Escudier
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Ramucirumab (RAM) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) Following First-Line Therapy with Sorafenib: Analyses from the Randomized Phase III REACH Study
2015
·
C. Barone
, G. Brandi
, et al.
·
Annals of Oncology
·
1
34 Belzutifan Plus Lenvatinib Versus Cabozantinib in Post–PD-(L)1 Renal Cell Carcinoma: Health-Related Quality-of-Life Outcomes in the Phase 3 LITESPARK-011 Study
2026
·
Manuela Schmidinger
, Daniel Y C Heng
, et al.
·
The Oncologist
PDF
Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and liver metastasis: Subgroup analysis of the phase 3 CheckMate-9ER trial.
2026
·
Amishi Yogesh Shah
, Bernard Escudier
, et al.
·
Journal of Clinical Oncology
PDF
Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium
2026
·
Martin Zarba
, David Maj
, et al.
·
Clinical Genitourinary Cancer
PDF
2673eP Integrating genomic profiling into metastatic renal cell carcinoma (mRCC) management: Real-world insights on prediction and treatment
2025
·
M. Rizzo
, G. Pezzicoli
, et al.
·
Annals of Oncology
179P Genomic profiling in hepatocellular carcinoma: A real-world retrospective analysis
2025
·
F. Salani
, F.R. Ponziani
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
19
Citation count:
10
H-index:
2
I10-index:
Year
Topic
Type